Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Unmet needs in amyloidosis

Suzanne Lentzsch • 1 Sep 2020
SOHO 2020
Amyloidosis Rare Diseases Antibodies Daratumumab

Suzanne Lentzsch, MD, PhD, Columbia University and New York Presbyterian Hospital, New York, NY, outlines unmet needs in the treatment of amyloidosis, including ensuring early and correct diagnosis, as well as achieving a deep and long-term remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Suzanne Lentzsch

2:38
How to treat AL amyloidosis in 2020?
Suzanne Lentzsch • 31 Aug 2020
2:55
Chemotherapy-free approaches to AL amyloidosis
Suzanne Lentzsch • 27 Aug 2020
8:47
Highlights in multiple myeloma at ASCO 2020
Suzanne Lentzsch • 29 May 2020
4:07
The potential of anti-amyloid antibodies to treat amyloidosis
Suzanne Lentzsch • 12 Sep 2018

Related Videos

1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
1:07
Key advancements in the treatment of BPDCN from EBMT 2024
Cristina Papayannidis • 22 Apr 2024
1:27
First-line tagraxofusp followed by alloSCT in BPDCN: a case study
Cristina Papayannidis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals